Land: USA
Språk: engelsk
Kilde: NLM (National Library of Medicine)
SODIUM PHENYLACETATE (UNII: 48N6U1781G) (PHENYLACETIC ACID - UNII:ER5I1W795A), SODIUM BENZOATE (UNII: OJ245FE5EU) (BENZOIC ACID - UNII:8SKN0B0MIM)
Mylan Institutional LLC
SODIUM PHENYLACETATE
SODIUM PHENYLACETATE 100 mg in 1 mL
INTRAVENOUS
PRESCRIPTION DRUG
Sodium phenylacetate and sodium benzoate injection is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [see Warnings and Precautions (5) ]. None. Available data with sodium phenylacetate and sodium benzoate injection use in pregnant women are insufficient to identify a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Animal reproduction studies have not been conducted with sodium phenylacetate and sodium benzoate injection. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. g
Sodium Phenylacetate and Sodium Benzoate Injection, 10% per 10% is supplied in a sterile, non-pyrogenic, single-dose glass vial. NDC 67457-844-50 single-dose vial containing 50 mL of sodium phenylacetate and sodium benzoate injection, 10% per 10% Storage: Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).
Abbreviated New Drug Application
SODIUM PHENYLACETATE AND SODIUM BENZOATE- SODIUM PHENYLACETATE AND SODIUM BENZOATE INJECTION, SOLUTION, CONCENTRATE MYLAN INSTITUTIONAL LLC ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE SODIUM PHENYLACETATE AND SODIUM BENZOATE INJECTION SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR SODIUM PHENYLACETATE AND SODIUM BENZOATE INJECTION. SODIUM PHENYLACETATE AND SODIUM BENZOATE INJECTION, FOR INTRAVENOUS USE INITIAL U.S. APPROVAL: 1987 INDICATIONS AND USAGE Sodium phenylacetate and sodium benzoate injection is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. (1) DOSAGE AND ADMINISTRATION • • • DOSAGE FORMS AND STRENGTHS Injection: 10% per 10% sterile, concentrated, aqueous solution of sodium phenylacetate and sodium benzoate. (3) CONTRAINDICATIONS None (4) WARNINGS AND PRECAUTIONS • • • • • ADVERSE REACTIONS The most frequently reported adverse reactions (incidence ≥ 6%) are vomiting, hyperglycemia, hypokalemia, convulsions, and mental impairment. (6) TO REPORT SUSPECTED ADVERSE REACTIONS, CONTACT MYLAN AT 1-877-446-3679 (1-877-4-INFO- RX) OR FDA AT 1-800-FDA-1088 OR WWW.FDA.GOV/MEDWATCH. DRUG INTERACTIONS • Sodium phenylacetate and sodium benzoate injection must be diluted with sterile 10% Dextrose Injection (D10W) before administration. Administration must be through a central venous catheter. Administration through a peripheral line may cause burns. (2) Sodium phenylacetate and sodium benzoate injection is administered intravenously as a loading dose infusion administered over 90 to 120 minutes, followed by an equivalent maintenance dose infusion administered over 24 hours. (2) See Full Prescribing Information for complete dosing recommendations. Decreased Potassium Levels: Plasma potassium levels should be carefully monitored and appropriate treatment given when necessary. ( read_full_document